

Cariprazine in patients with schizophrenia – real-life data analysis based on the NEAK database (HU-NIS-CARIPRAZINE-01/2024)

First published: 21/12/2024

Last updated: 15/01/2026

Study

Finalised

Administrative details

EU PAS number

EUPAS1000000422

Study ID

1000000422

DARWIN EU® study

No

Study countries

☐ Hungary

Study status

Finalised

Research institutions and networks

Institutions

Gedeon Richter

First published: 01/02/2024

Last updated: 01/02/2024

Institution

Contact details

Study institution contact

Zsombor Kovács kovacszsom@gedeonrichter.com

Study contact

kovacszsom@gedeonrichter.com

Primary lead investigator

Darko Djuric

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 17/12/2024

Actual: 17/12/2024

Study start date

Planned: 01/01/2025

Actual: 05/02/2025

Date of final study report

Planned: 28/02/2025

Actual: 28/11/2025

Sources of funding

- Pharmaceutical company and other private sector

Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type

Study type list

Study topic:

Human medicinal product

Study type:

Non-interventional study

Scope of the study:

Drug utilisation

Data collection methods:

Secondary use of data

Study Design

Non-interventional study design

Cohort

Study drug and medical condition

Study drug International non-proprietary name (INN) or common name

CARIPRAZINE HYDROCHLORIDE

OLANZAPINE

ARIPRAZOLE

RISPERIDONE

Anatomical Therapeutic Chemical (ATC) code

(N05AX15) cariprazine

cariprazine

(N05AX12) aripiprazole

aripiprazole
(N05AH03) olanzapine
olanzapine
(N05AX08) risperidone
risperidone

Medical condition to be studied

Schizophrenia

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025.
The ENCePP Seal fields are retained in the display mode for transparency
but are no longer maintained.

Data sources

Data source(s), other

Database maintained by National Health Insurance Fund (Hungarian acronym:
NEAK) in Hungary

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Yes

Check completeness

Unknown

Check stability

Yes

Check logical consistency

Yes

Data characterisation

Data characterisation conducted

Yes